Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis licenses groundbreaking new diabetes treatment

Sanofi-aventis licenses groundbreaking new diabetes treatment

8th April 2010

Sanofi-aventis has agreed a worldwide licensing deal with biopharmaceutical company CureDM over a potentially groundbreaking regenerative diabetes treatment.

The French firm has agreed to pay up to $335 million (220.3 million pounds) plus royalties for rights to Pancreate, a peptide which could restore the ability to produce insulin among type 1 and type 2 diabetes patients.

Under the terms of the deal, Sanofi-aventis will take responsibility for the development, production and commercialisation of the treatment, with CureDM receiving payments based on clinical milestones.

Dr Marc Cluzel, executive vice-president of research and development at Sanofi-aventis, said the drug could help to restore normal pancreatic function for diabetes sufferers.

He added: “Pancreate has the potential to become the first regenerative treatment of type 1 and type 2 diabetes and to address the challenges that the growing diabetes epidemic poses to patients.”

Earlier this month, the company agreed to partner with blood glucose monitoring specialist AgaMatrix to create new treatment options which will work in conjunction with Sanofi-aventis diabetes drugs.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.